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DNA methylation is an essential epigenetic modification that plays a key role associated with the regulation of gene
expression during differentiation, but in disease states such as cancer, the DNA methylation landscape is often deregu-
lated. There are now numerous technologies available to interrogate the DNA methylation status of CpG sites in a tar-
geted or genome-wide fashion, but each method, due to intrinsic biases, potentially interrogates different fractions of the
genome. In this study, we compare the affinity-purification of methylated DNA between two popular genome-wide
techniques, methylated DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain-based capture (MBDCap),
and show that each technique operates in a different domain of the CpG density landscape. We explored the effect of
whole-genome amplification and illustrate that it can reduce sensitivity for detecting DNAmethylation in GC-rich regions
of the genome. By using MBDCap, we compare and contrast microarray- and sequencing-based readouts and highlight the
impact that copy number variation (CNV) can make in differential comparisons of methylomes. These studies reveal that
the analysis of DNA methylation data and genome coverage is highly dependent on the method employed, and con-
sideration must be made in light of the GC content, the extent of DNA amplification, and the copy number.
[Supplemental material is available online at http://www.genome.org. The data from this study have been submitted to
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) under SuperSeries accession no. GSE24546.]
DNA methylation, which is one of the most studied epigenetic
marks, involves the addition of a methyl group to the 5 position
of the cytosine pyrimidine ring and occurs primarily at CpG di-
nucleotides in mammals ( Jones 1999). DNAmethylation patterns
are established early in development and are associated with the
regulation and maintenance of gene expression during differenti-
ation (Sorensen et al. 2010). Methylation patterns can also be dis-
rupted in many disease states, and in particular, changes in DNA
methylation at CpG island-associated promoters can play a role in
the development of cancer ( Jones and Baylin 2002, 2007; Jaenisch
and Bird 2003).
There are now numerous methods available for determining
CpG methylation status (for review, see Laird 2010), including
methods focused at the level of CpG islands (Ponzielli et al. 2008;
Kaminsky et al. 2009), individual promoters (Weber et al. 2005,
2007; Novak et al. 2008), and, increasingly, genome-‘‘scale’’
(Meissner et al. 2008; Gu et al. 2010) and genome-wide methods,
either at high (Lister et al. 2009) or low resolution (Serre et al. 2009;
Ruike et al. 2010). These later methods can be broadly classified
into the following designations: reduced representation approaches
that are based on methylation-sensitive (e.g., HELP) (Oda et al.
2009) or specific (e.g., CHARM) (Irizarry et al. 2008) restriction
digestion (for review, see Jeddeloh et al. 2008), affinity-based
methods such as methyl-DNA immunoprecipitation (MeDIP)
(Weber et al. 2005, 2007; Novak et al. 2008) and methyl-CpG
binding domain-based capture (MBDCap) (Rauch et al. 2006,
2008; Serre et al. 2009), and themoredirect bisulphite treatment-based
methods (Lister et al. 2009); coupling of reduced representation and
bisulphite treatment has now been demonstrated (Meissner et al.
2008; Gu et al. 2010), and other combinations are also possible.
However, there are still many challenges involved in interpreting
data from DNA methylation-based assays, due to complex effects,
both technical and biological that are introduced at various steps
in the procedure, in addition to implicit biases from the methods
employed. These include cellular purity and DNA quality, DNA
amplification bias in GC-rich regions, and the effects of copy
number aberrations. The focus of this study is on DNAmethylation
analyses using affinity-based approaches, in combination with
promoter DNA microarrays or high-throughput DNA sequencing
readouts.
Chromatin immunoprecipitation (ChIP) has been used ex-
tensively to study protein–DNA interactions (Ren et al. 2000), and
recently, an extensive benchmarking study has been conducted
comparing microarray platforms and analysis methods ( Johnson
et al. 2008). Comparison studies for DNA methylation platforms
are now starting to emerge (Li et al. 2010). MeDIP uses an antibody
to 5-methyl-cytosine, targeting single-stranded DNA (Weng et al.
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2009; Ruike et al. 2010), while the MBDCap approach uses the
methyl-CpG binding domain of the MBD2 protein to capture
double-strandedDNA (Serre et al. 2009). Furthermore, theMBDCap
approach can use a series of salt fractionation steps that allows
specific methylation density to be assessed (Fig. 1A). Methylation
status of the immunoprecipitated DNA isolated from MeDIP or
MBDCap is analyzed using tiling microarrays or high-throughput
sequencing, and multiple platforms of each are available. Because
DNA is often limiting and derived frommixed cell types, especially
in studieswith clinical samples, it canbedifficult to isolate sufficient
amounts of pure DNA to hybridize to microarrays directly or to se-
quence. DNA amplification techniques have been developed to
address this problem (Paris 2009). Here, we show that DNA ampli-
fication can result in depletion of GC-rich regions and therefore
may particularly impact on the interpretation of DNA methylation
in CpG islands. Most importantly, copy number variation (CNV)
can impact on the interpretation of DNAmethylation levels, and in
cancer, this can be critical within the regions harboring gene am-
plification and/or deletions. Furthermore, promoter tiling array data
can be used to adjust for copy number changes, and we show that
copy number aberrations can have a significant impact on genome-
wide DNA methylation analysis.
Results
MeDIP and MBDCap enrich different fractions
of the genome based on CpG density
MeDIP and MBDCap are two capture methods commonly used
to interrogate genome-wide DNA methylation patterns. These two
techniques have inherent differences, namely, antibody versusMBD
capture. We asked if each method was comparable in the detection
of the same methylated genomic DNA sequences. Fully methylated
human genomic DNA treated with SssI methyltransferase was used
to benchmark the two affinity-based DNA methylation mapping
platforms. For the MBDCap comparison, the MethylMiner protocol
was used, where DNA can be eluted in a high-salt buffer (2 M NaCl)
as a single fraction, here referred to as MBD-SF, or eluted as distinct
subpopulations based on the degree of methylation, using an in-
creasing concentration of NaCl from 200 mM to 2000 mM. MBD-
Elu5 denotes the 1M fraction of the elution series (Fig. 1A). After SssI
treatment, essentially every CpG site in the genome is methylated,
allowing a direct comparison of enrichment between MeDIP and
MBDCap, which was interrogated using Affymetrix Human Pro-
moter 1.0R arrays containing more than 4.5 million 25mer probes
spanning 23,155 promoters. Figure 1B shows summarized input-
subtracted promoter tiling array signals from MeDIP, MBD-Elu5,
and MBD-SF of fully methylated DNA after stratifying probes
according to the local genomic CpG density (for a formal definition,
seeMethods). Several keyobservations can bemade: First, the overall
degree of enrichment is higher for MBDCap-based procedures, es-
pecially for CpG-dense methylated DNA (probes with high local
Figure 1. (A) Schematic showing the capture of methylated DNA into
populations of single-stranded (MeDIP) or double-stranded (MBDCap)
fragments. (B) Summarized probe intensities for enrichment of fully
methylated DNA with MeDIP and two variations of MethylMiner-based
enrichment. X-axis shows the local CpG density group (1–50). Y-axis
shows the log2-scale input-normalized intensity. Each line shows the
median intensity for the input-normalized intensities for the probes in the
bin (here, for probes with GC content of 11 only). The intensities are
further normalized such that the median in the lowest bin is 0. The loca-
tion of probes within CpG islands is shown by the gray-shaded region,
corresponding to a local CpG density score between 12 and 40. (C )
Summarized read counts in bins of 1000 bases over the same genomic
regions interrogated by the Affymetrix Promoter 1.0R array. Each line
represents the median log2 read count (RCpM indicates read counts per
million mapped); the summaries are normalized such that the median
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CpG density); second, due to the nature of the salt elution steps,
MBD-Elu5 enriches primarily for CpG-dense material only, whereas
MBD-SF enriches for a broader range of CpG densities, albeit at a
lower average level. An attenuation of promoter microarray signal
was observed at the highest CpG density regions, and notably, the
attenuation seems to occur at a higher local CpG density for the
MethylMiner-based procedure than MeDIP. As MeDIP recovers
single-stranded DNA and MBDCap recovers double-stranded DNA,
it is possible that topoisomerase activity from M.SssI may com-
promise amplification of DNA recovered from MeDIP relative to
MBDCap (Matsuo et al. 1994). However, we found that enrichment
levels of methylated LNCaP DNA were also favored by MBDCap
in comparison to MeDIP for CpG dense regions, albeit at reduced
levels (Supplemental Fig. 1), supporting the use of MBDCap-based
procedures for favoring interrogation of CpG-rich regions.
Next we asked if the apparent CpG bias was also observed
with sequencing data. Similar to the previous experiment, fully
methylated DNA was used to perform the MBDCap enrichment,
and we analyzed the eluted DNA using a high-throughput sequenc-
ing readout. Using one lane of Illumina Genome Analyzer sequenc-
ing with 36-base single end reads for each ofMBD-Elu5 andMBD-SF,
8,616,022 and 11,557,035 uniquely mapped reads were obtained,
respectively, to the reference human genome (see Methods). In
order to compare themethylation readout against promoter arrays,
the number of reads (in nonoverlapping 1000-bp bins) mapping
to the subset of the genome interrogated by the Affymetrix tiling
array was calculated. Figure 1C shows the read counts normalized
to depth, similarly grouped by local CpG density. Supplemental
Figure 2 shows enrichment profiles across the whole genome,
highlighting the different profile of enrichment (andCpGdensity)
of promoters compared to the entire genome. The CpG density
bins in Figure 1C represent approximately the local CpG den-
sity bins in Figure 1B, but the enrichment levels are not directly
comparable. Overall, a similar enrichment profile was observed
for the sequencing data, where MBD-Elu5 enriches for densely
methylated regions and MBD-SF enriches for a slightly broader
range ofCpGdensity. As before, a slight drop in thenumber of reads
in very highCpGdensity regions was observed, but not to the same
extent as observed in the tiling array data. It is not clear whether the
decrease can be attributed to PCR-based amplification in the library
preparation or cluster generation step, or whether there are other
biases introduced inmapping reads to the genome, or whether this
is an inherent property of the affinity-based techniques.
Whole-genome amplification can bias DNA methylation
calls in CpG dense regions
Given the signal attenuation observed in the fully methylated
enrichment experiments, we next examined if this is due towhole-
genome amplification (WGA), a required step in the protocol to
generate enoughmaterial for hybridization to the promoter arrays. It
is well established that the GC content of a DNA template can affect
the efficiency of amplification, often resulting in a bias against the
GC-rich regions of the genome (Bredel et al. 2005; Pugh et al. 2008;
Teo et al. 2008). Johnson et al. (2008) also report a significant drop in
sensitivity,most notably for Affymetrix tiling arrays, whenamplified
DNA is hybridized. Amplification bias is perhaps even more of a
potential concern in DNAmethylation mapping, since CpG islands
are GC-rich by their very nature and therefore more prone to any
extant bias.
We were initially alerted to a potential problem involving GC
bias when GSTP1, which is highly methylated at its CpG island-
associated promoter in prostate cancer and is unmethylated in
normal cells (Song et al. 2002; Nakayama et al. 2004), showed little
differential enrichment at the probe-level on the Affymetrix pro-
moter tiling arrays after MeDIP enrichment and WGA of prostate
cancer (LNCaP) and normal prostate epithelial cells (PrECs) (see
Supplemental Fig. 3A; Coolen et al. 2010). MeDIP-qPCR experi-
ments, used as a control before hybridization, confirmed a strong
affinity of methylated DNA at the GSTP1 locus, both before (77-
fold) and after (76-fold) amplification (Supplemental Fig. 3B). Con-
sequently, even though the degree of enrichment was maintained
between LNCaP and PrECs, the absolute copy number of GSTP1
molecules in the population decreased proportionally after WGA,
from 676 and 8.7 copies/ng beforehand to 32 and 0.43 copies/ng
afterward, respectively. These data suggest that DNA amplification
can result in an apparent loss of methylation detection for regions
of the genome that are amplified less efficiently, such as GC-rich
regions. To illustrate this further, Supplemental Figure 4 shows
probe-level data for the CpG-rich promoters of WNT2 and CAV2
and the CpG-poor promoters of AGR2, PTN, and SOSTDC1, all of
which are validated to be hypermethylated in prostate cancer
cells. For the WNT2 and CAV2 promoters, the microarray signal
representing differential methylation is observed only in regions
flanking the CpG island. We hypothesize that WGA has ablated
the absolute levels of these DNA molecules, similar to GSTP1.
Notably, the AGR2, PTN, and SOSTDC1 promoters, which are of
lower CpG content, exhibit a differential signal throughout the
region validated to be differentially methylated. It is realistic to
expect that many GC-rich regions, such as CpG islands, while
differentially enriched between populations before amplification,
become diluted to be below the lower detection limit on the pro-
moter microarray after WGA.
By using Affymetrix promoter tiling array data, the effect of
WGAwas studied directly by comparing the probe intensities from
unamplified and amplified DNA from the same origin. For this
experiment, genomic input DNA was used, without a methylated
DNA affinity step. Figure 2 shows the distribution of the raw pro-
moter array signal intensity for both an unamplified and WGA
sample of the same input genomic DNA, across equally sized bins
of local CpG density. Here, only probes with a GC content of 8, 11,
and 14 (of the 25-mer probe) (Supplemental Fig. 5 displays the full
range of probe GC contents) are displayed. Notably, a substantial
drop in the promoter tiling microarray signal is observed for the
probes in CpG-rich regions (local CpG density greater than 12 de-
fines aCpG island). In addition, CpG-rich regions of the genome also
show some attenuation in thehybridization signal fromunamplified
DNA when the probe GC content was greater than 11, suggesting
that other effects, such as cross-hybridization and probe-specific
temperature effects (Wei et al. 2008), may influence the signal ob-
served on microarrays. It is also noted that the observed CpG
density bias is not unique to the Affymetrix platform, since un-
amplified MeDIP-enriched fully methylated DNA samples ana-
lyzed on a NimbleGen platform (Gal-Yam et al. 2008) also exhibit
attenuation over probes with a broad range of GC contents (Sup-
plemental Fig. 6).
Since some form of genome-wide amplification is required to
obtain sufficient DNA for array experiments, we next asked if re-
cent variations to enhance the amplification of GC-rich regions
(Zhang et al. 2009) could reduce the attenuation observed on the
tiling arrays. Samples of unamplified genomic DNA with standard
WGA, additives with WGA (Betaine, DMSO, ethylene glycol, 1,2-
propanediol), and the different amplification conditions suggested
by Affymetrix for ChIP-chip experiments (Fig. 3) are compared. To
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summarize the results, a cumulative bias score was calculated to
quantify the signal attenuation in tiling array data across local CpG
density bins for each group of probes at a GC content (for details
of the bias score, see Methods; for explanation, see Supplemental
Fig. 7). As shown previously in Figure 2, more CpG-rich attenuation
(cumulative bias) at the higher probe GC content (greater than 11)
occurs for unamplified DNA (Fig. 3). However, all the different am-
plification conditions tested show a much greater bias score than
does unamplified DNA and did not reduce the signal attenuation
(Fig. 3).
Detection of differentially methylated regions
To explore the impact of these biases, we looked for differentially
methylated regions (DMRs) across the promoter regions represented
on the Affymetrix promoter tiling array, comparing the prostate
cancer (LNCaP) and normal epithelial (PrEC) cell lines. Using a sta-
tistical procedure similar to model-based analysis of tiling arrays
(MAT) (Johnson et al. 2006) at an estimated 5% false discovery rate
(see Methods), 7384, 4398, and 3815 DMRs were detected between
the two cell lines for MeDIP, MBD-Elu5, and MBD-SF, respectively.
Given the enrichment profiles from Figure 1, it is not surprising that
the detected DMRs showed CpG density distributions that reflect
the enrichment profile, as shown in Figure 4. The differentially
methylated promoters were split into hypermethylated (Fig. 4A)
andhypomethylated in cancer (Fig. 4B) to illustrate the asymmetry
in differential methylation between the cell lines. As expected,
MBD-Elu5 discovers substantially more DMRs in CpG-rich regions
and identifies the greatest proportion of CpG islands, and MBD-SF
finds DMRs in a broader range of CpG density, while MeDIP iden-
tifies the lowest percentage of CpG-rich regions.
Next, MBD-SF enriched DNA was analyzed from the two cell
lines using both promoter tiling array (MBDCap-chip) and high-
throughput sequencing (MBDCap-seq), allowing us to compare
directly the concordance of the two readouts. Since the tiling ar-
rays only measure promoters, the sequencing data were summa-
rized into bins of read counts at promoters so they could be directly
compared. The statistical procedures used to detect differentially
methylated promoters from the two platforms are fundamentally
different, due to the nature of the data (probe intensities vs. read
counts, see Methods). However, P-values should be on scales that
Figure 2. Box-and-whisker plots of unnormalized log2-scale microarray
intensities for unamplified and WGA-amplified genomic DNA. To control
for the association between probe GC content and intensity, probes with
GC content of 8, 11, and 14 (out of 25) are shown in A–C, respectively.
Plots for the remaining probe GC contents (and further experimental
samples) are shown in Supplemental Figure 5. Probes are grouped into 50
equally sized bins genome-wide-based on their local CpG density, as
shown in Figure 1, B andC. Box-and-whisker plots show the 25th and 75th
percentile as the bottom and top of the box, and the band represents the
median; the whiskers show the lowest data point within 1.5 interquartile
range (IQR) of the 25th percentile and the highest data point within 1.5
IQR of the 75th percentile.
Figure 3. Observed cumulative bias of various amplification methods.
X-axis denotes the probe GC content. Y-axis denotes the cumulative bias
score, which captures the cumulative signal attenuation over the 50 bins
of local CpG density (for definition, see Methods). Each line represents
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are directly comparable. The P-values from each platform are back-
transformed into Z-scores (i.e., quantiles of a standard normal
distribution) to summarize the evidence for differential methyla-
tion, signed according to the direction of the change. Differential
methylation Z-scores for both platforms are shown in Figure 5A.
As expected, there is a general concordance (r = 0.46) since the
two platforms are comparing enriched DNA from the same origin.
One noticeable difference between the platforms is the range of
Z-scores, with sequencing data giving a much larger range of evi-
dence for differential methylation. Although it is not certain that
every promoter-level difference above a threshold is indeed dif-
ferentially methylated, the much wider range of Z-scores suggests
the sequencing-based data have a higher sensitivity. Furthermore,
comparison of MBDCap-seq data and quantitative Sequenom
bisulphite-based DNA methylation data highlights a strong con-
cordance (r = 0.81) (Supplemental Fig. 8). Figure 5A highlights that
all six hypermethylated genes discussed previously are called dif-
ferentially methylated by one of the readouts. Notably, the GSTP1
CpG island promoter shows a significantly higher number of reads
in the region around the gene’s transcription start site (TSS) for the
cancer cells, but similar to the MeDIP-chip data (Fig. 5A), there
is little evidence of differential methylation from the MBDCap-
chip data (Supplemental Fig. 8). Similarly, the promoter of CAV2, a
CpG-rich region, shows strong differential methylation for the
sequencing but not for themicroarray. The promoters of SOSTDC1
and AGR2, from low CpG density regions, are found by the micro-
array and only show moderate differential methylation in the se-
quencing data (Supplemental Fig. 9). Differential methylation calls
for PTN andWNT2 are reasonably concordant. Furthermore, if a
Z-score cutoff of three is set, the promoter array only detects 256
of the 2854 promoters detected by the sequencing data as differ-
entially methylated, suggesting that its sensitivity is much lower.
However, the tiling array also finds 246 regions differentially meth-
ylated that the sequencing data does not, suggesting there may also
be inherent biases in the genomic regions that are suitable for
sequencing.
We next explored the CpG density of the concordant and
discordant promoters (as defined by Z-score cutoffs; see Methods)
that were detected using the two platforms (Fig. 5B), split into
groups of hyper- and hypomethylated regions. The array-based
Figure 4. Box-and-whisker plots of CpG density for putative DMRs (at estimated false discovery rate of 5%) between LNCaP and PrEC cells. Shown are
hypermethylated (A) and hypomethylated (B) regions.
Figure 5. Comparison of MBD-SF tiling array and sequencing data. (A) Differential methylation Z-scores between LNCaP and PrEC cells using MBD-
SF-seq (y-axis) and MBD-SF-chip (x-axis). The six validated genes that are shown in Supplemental Figures 3A and 4 are indicated with black dots. The
remaining dot colors are chosen according to the differential methylation concordance between MBD-SF-seq and MBD-SF-chip Z-score as depicted in B.
Note that some truly differentially methylated promoters, such as WNT2, are deemed ‘‘Indeterminate’’ by this concordance classification. (B) Box-and-
whisker plots of CpG density for concordant and discordant differentially methylated promoters, with colors corresponding to the cutoffs shown in A. (C )
Box-and-whisker plots of sequencing mapability of the concordant and discordant differentially methylated promoters, using the colors from A.
Evaluation of genome-wide methylation data
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readout detects a smaller percentage of CpG-rich regions in com-
parison with the sequencing-based data, supporting the observa-
tion that DNA amplification and other biases have a direct im-
pact on the regions detected. The majority of regions detected by
microarray and not by sequencing are in low CpG density regions.
Conversely, sequencing-only detections are largely from CpG-rich
regions. Furthermore, promoters deemed differentiallymethylated
by microarray but not by sequencing, on average, have lower
mapability (Fig. 5C). However, it should be noted that the probes
in these same microarray-only detected regions exhibit a slightly
higher probe copy number (see Supplemental Fig. 10).
The number of differentiallymethylated promoters identified
by sequencing data is ultimately dependent on read depth. To es-
timate whether the saturation of promoter differential methylation
has been achieved with the current sequencing depth, the MBD-
SF-seq data set for LNCaP cells and PrECs was down-sampled at
various fractions, and a curve was fitted to the number of differen-
tiallymethylated promoters. The presented experiments capture an
estimated 60%–68% of the differentially methylated promoters,
while doubling the number of mapable reads will result in an es-
timated 78%–89% sensitivity (seeMethods; Supplemental Fig. 11).
Copy number, input DNA, and DNA methylome data
Another important yet subtle aspect of identifying epigenetic
changes, especially in a cancer setting, is the impact of copy number
aberrations on the DNA methylation signal. Copy number aberra-
tions canhave a direct effect on transcript levels (Stranger et al. 2007).
The effect is less clear in DNA methylome data, but the expectation
is that genetically amplified (deleted) regions of the genome should
be captured at a higher (lower) rate if the DNA is methylated. In
the analysis of the ChIP-chip experiments, it is common practice to
subtract the genomic DNA input signals from the immunoprecipi-
tation signals in order to account for copy number, while indirectly
this adjustment can also account for hybridization, sonication, or
probe-specific effects. In two-color microarray experiments, this ad-
justment is done explicitly (Gal-Yam et al. 2008). Early sequencing-
based DNAmethylation mapping exercises have not included input
DNA controls (Serre et al. 2009), and if included, biases are known
to exist (Teytelman et al. 2009; Vega et al. 2009). It is highlighted
here that signals from the input DNA can adequately identify copy
number aberrations, and this knowledge will be critical to disen-
tangling differential methylation from changes in copy number.
To validate the use of genomic input DNA tiling array data to
account for copy number changes, Affymetrix SNP 6.0 array data
were collected on the same two cell lines that have genome-wide
DNA methylation data. To define copy number changes between
the two cell lines, the input DNA tiling arrays were processed
similarly to the gene expression data, resulting in a promoter-level
summary of the change in copy number after accounting for
probe-specific effects (see Methods) (Irizarry et al. 2003). Figure 6
shows the change in copy number between the two cell lines for
chromosome 5 (for all other chromosomes, see Supplemental Fig.
12), emphasizing the strong association between promoter-level
summaries of genomic input DNA on the promoter tiling array
(Fig. 6A), and summarized SNP and copy number probes from the
genotyping arrays (Fig. 6B). It also demonstrates the potential of
using promoter-level summaries of input DNA signals for discov-
ering copy number aberrations in the absence of directly collecting
SNP array data or similar. Figure 6C shows the relationship be-
tween smoothed estimates of copy number (see Methods) for the
twoplatforms, suggesting the genome-wide correspondenceof copy
number changes is quite high (r = 0.86).
Next, we highlight that the effects of copy number aberra-
tions are prominent in affinity-based epigenomedata, affecting both
DNA methylation and ChIP assays. The differential methylation
Figure 6. Using promoter tiling arrays to estimate changes in copy number. (A) Y-axis is the difference in copy number between the prostate cancer and
normal epithelial cell line using the Affymetrix Promoter 1.0R array along human chromosome 5. The gray line represents kernel-smoothed differences
over 200 kb. (B) Y-axis shows the difference in copy number using the Affymetrix SNP 6.0 array along the same region of chromosome 5. The gray line
represents kernel-smoothed differences over 50 kb. (C ) X-axis and y-axis represent the smoothed copy number changes between the prostate cancer and
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detection exercise (using MBD-SF on prostate cancer LNCaP and
PrEC lines) was extended to the entire genome, using read counts
over 1500 base pair bins, and Z-scores were computed for each re-
gion. Figure 7A illustrates changes in MBDCap-seq read counts
along chromosome 13. As expected, they are correlatedwith changes
in copy number (Fig. 7B) for the same regions. Figure 7C shows the
distribution of DMR Z-scores genome-wide, stratified by their cor-
responding change-in-copy-number status. Taken together, these
observations underscore the need to integrate CNV explicitly with
epigenome analyses. Interestingly, there is a large (;10Mbase pairs)
region near 70 MB on chromosome 13 that shows deletion (SNP
array data), but no corresponding change inmethylation (MBDCap-
seq). The MBDCap-seq data from the rest of this chromosome sug-
gest that it is a region of hypermethylation, implying a potential
link between regional hypermethylation and genome stability.
Discussion
With the rapid growth of the different genome-wide technologies
available for DNA methylation analysis (Lister et al. 2009; Oda
et al. 2009; Serre et al. 2009; Ruike et al. 2010), it is timely to stop
and reevaluate the limitations and benefits of the different tech-
niques. We have evaluated the technical and data analysis aspects
of promoter-level tiling microarray and genome-wide sequencing-
based DNA methylation data and find that there are several hur-
dles that need to be overcome before a high sensitivity platform
with genome-wide methylation coverage will emerge. Perhaps not
unexpectedly, different enrichment techniques and readouts give
different snapshots of the DNA methylome. Knowledge of in-
herent biases and limitations of each method should encourage
protocol improvements and facilitate data integration from mul-
tiple platforms, as well as the development of improved bioinfor-
matics tools to extract meaningful biological interpretation.
Comparisons of affinity-based methylome mapping tech-
niques are now beginning to appear (Li et al. 2010). Here, a com-
parison of MBDCap- and MeDIP-based affinity capture strategies
was performed, as well as a comparison of promoter tiling arrays
and sequencing-based readouts. In addition,wehighlight the tech-
nical limitations due to WGA, describe a novel method to assess
amplification genome-wide with tiling arrays, and illustrate bio-
logical biases attributable to copy number that are relevant to the
effective analysis of the DNA methylome. By using fully methyl-
ated DNA and LNCaP DNA, enrichment profiles were compared
across the CpG density spectrum of MeDIP and two versions of
MBDCap: MBD-Elu5, the 1000-mM fraction that elutes densely
methylated DNA, and MBD-SF, a single elution encompassing all
methylated fractions. Our data reveal higher overall enrichment
using themethyl DNA binding domain protocol fromMethylMiner,
compared with immunoprecipitation with the 5-methylcytosine
monoclonal antibody, especially in CpG-rich regions. MBD-Elu5
preferentially elutes CpG-rich DNA, while MBD-SF contains DNA
molecules spanning a broader range of CpG densities. For all
methods analyzed by promoter microarrays, a marked drop in sig-
nal intensity was observed at the CpG-dense regions, including at
many of the CpG islands. This attenuation was found to be largely
due to WGA but is also confounded by other effects, such as GC
content of the microarray probes and cross-hybridization, which
affects the signal and therefore sensitivity and dynamic range.
Interestingly, CHARM has compared favorably in performance to
MeDIP (Irizarry et al. 2008) and notably without an amplification
step. However, CHARM does require large amounts of starting DNA
and is typically used with a custom microarray.
Unfortunately for the MeDIP and MBDCap approaches, it is
rarely feasible to get sufficient affinity-purified DNA for genome-
wide analyses, thereby necessitating amplification before hybrid-
ization to microarrays. In some cases, pooling multiple samples
may be a reasonable alternative, but this results in a loss of valuable
replicate information. Furthermore, pooling affinity-purified DNA
is often not practical when analyzing DNA from low cell numbers,
such as formalin-fixed paraffin-embedded clinical samples. Our
results suggest that amplification reduces sensitivity and permits
only a subfraction of the genome to be interrogated. Specifically,
tiling array probes representing CpG-rich regions, which are argu-
ably of greatest interest for methylation mapping, appear to show
a lower intensity and a compressed dynamic range. As a result, the
ability to detect differential methylation using amplified DNA is
compromised at many CpG islands.
Sequencing-based assays require less starting material. How-
ever, amplification during the sequencing protocol also has the
potential to introduce some sequence bias in CpG-rich regions,
albeit to a lesser extent. Promoter tiling array and high-throughput
sequencing readouts of the same populations of MBDCap-enriched
methylated DNA were compared. Even though the concordance is
strong, it is the discordance that highlights the differences in the
Figure 7. Effects of copy number changes on differential methylation detection. (A) Differential methylation Z-score for between LNCaP and PrEC cells,
using MBD-SF-seq, for human chromosome 13. (B) Smoothed Affymetrix SNP 6.0 array data showing corresponding changes in copy number. (C )
Genome-wide distributions of Z-scores, stratified by the change-in-copy-number status of the corresponding regions.
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platform-specific snapshots of the methylome. DMRs that are de-
tected by sequencing and not by microarray are commonly located
in the CpG-rich regions of the genome, validating the loss in sen-
sitivity on microarrays that is partly attributable to WGA. Further-
more, sequencing-based assays are strongly affected by enrichment
levels, such that highly enriched regions are sequenced to a greater
depth, resulting in higher power to detect changes. Therefore,
microarrays may be better suited to interrogating regions of lower
enrichment, such as those in lower CpG density areas, where the
cost of sequencing to obtain sufficient coverage may become lim-
iting. To a smaller extent, someof theDMRsdetectedbymicroarrays
and not by sequencing are in regions of lower ‘‘mapability,’’ sug-
gestingmicroarraysmay have improved sensitivity in these regions,
if unique probes can be designed. Furthermore, the extent to which
the genomic repeat elements are present in affinity-captured meth-
ylated DNA is largely unknown. Longer or paired-end reads will re-
sult in higher mapability, while paired-end reads will be essential
to studying the effects of repeat elements. Overall, sequencing data
appear to be more sensitive for the discovery of DMRs, in terms of
total detections, and they carry the obvious advantage that the entire
genome can be interrogated. However, the complexities introduced
by the enrichment levels, the amount of sequencing used, amplifi-
cation, methylated repeat elements, CpG density, and mapability
are cumulatively significant, suggesting that array and sequencing
platforms may be complementary for cost-effective and compre-
hensive analysis of differential methylation.
Last, we studied the subtle effects that CNV may introduce
into DNAmethylation data sets. The use of input DNA hybridized
to tiling arrays for economical copy number aberration detection
was validated, and we highlighted that genetic changes can sig-
nificantly confound the identification of epigenetic differences, if
not explicitly integrated into the analysis. This will be of particular
importance when analyzing cancer methylomes, for example,
where copy number aberrations are widespread. Extrapolation of
the information within existing copy number databases or from
existing genomic DNA microarray or arrayCGH data should be
straightforward. However, the implication of our results is that, in
some cases, additional resourceswill need to be dedicated to collect
CNV information (e.g., CNV-seq) (Xie and Tammi 2009). Copy
number biases will not only confound genome-wide methylation
analyses but will also be present in other affinity-based epigenome
mapping exercises, such as chromatin immunopreciptation ex-
periments studying histone modifications.
Many exciting new approaches have recently emerged to
study genome-wide DNA methylation (Clarke et al. 2009; Lister
et al. 2009; Flusberg et al. 2010), and along with these novel ap-
proaches have come an abundance of challenges, mainly associ-
ated with the interpretation of the growingmasses of data. A better
understanding of these technologies and the impact of current
laboratory protocols, such as MeDIP and MBDCap, will go a long
way toward the development of suitable and sensitive protocols for
the genome-wide analysis of the methylome.
Methods
Cell lines and culture conditions
LNCaP prostrate cancer cells were cultured as described previously
(Song et al. 2002). Normal PrECs (Cambrex Bio Science catalog
no. CC-2555) were cultured according to the manufacturer’s in-
structions in Prostate Epithelial Growth Media (PrEGM; Cambrex
Bio Science catalog no. CC-3166).
Methylation profiling by MeDIP
DNA was extracted from the cell lines using the Puragene extrac-
tion kit (Gentra Systems). For fully methylated positive control
DNA, CpG genome universal methylated DNA was obtained from
Millipore (catalog no. 57821). The MeDIP assay was performed
on 4 mg of sonicated genomic DNA (300–500 bp) in 13 IP buffer
(10 mM sodium phosphate at pH 7.0, 140 mM NaCl and 0.05%
Triton X-100). Ten micrograms anti-5-methylcytosine mouse
monoclonal antibody (Calbiochem clone 162 33 D3 catalog no.
NA81) was incubated overnight in 500 mL 13 IP buffer, and the
DNA/antibody complexes were collected with 80 mL Protein A/G
PLUS agarose beads (Santa Cruz sc-2003). The beads were washed
three times with 13 IP buffer at 4°C and twice with 1 mLTE buffer
at room temperature. The immune complexes were eluted with
freshly prepared 1% SDS and 0.1 M NaHCO3, and the DNA was
purified by phenol/chloroform extraction and ethanol precipita-
tion and resuspended in 30 mL H2O. Input samples were processed
in parallel.
Isolation of methylated DNA by MBDCap
The MethylMiner Methylated DNA Enrichment Kit (Invitrogen)
was used to isolate the methylated DNA. One microgram of ge-
nomic DNA was sonicated to 100–500 bp. Then 3.5 mg (7 mL) of
MBD-Biotin Protein was coupled to 10 mL of Dynabeads M-280
Streptavidin according to the manufacturer’s instructions. The
MBD-magnetic beads conjugates were washed three times and
resuspended in 1 volume of 13 bind/wash buffer. The capture re-
action was performed by adding 1 mg sonicated DNA to the MBD-
magnetic beads on a rotating mixer for 1 h at room temperature.
All capture reactions were done in duplicate. The beads were
washed three times with 13 bind/wash buffer. The methylated
DNA was eluted in one of two ways: (1) as a single fraction with a
high-salt elution buffer (2000 mM NaCl), denoted MBD-SF; or (2)
as distinct subpopulations based on the degree of methylation
using an increasing NaCl concentration of the elution buffer, from
200 mM to 2000 mM in a stepwise gradient (elution 1, 200 mM;
elution 2, 350mM; elution 3, 450mM; elution 4, 600mM; elution
5, 1000 mM; and elution 6, 2000 mM). Each fraction was con-
centrated by ethanol precipitation using 1mL glycogen (20mg/mL),
1/10th volume of 3 M sodium acetate (pH 5.2), and two sample
volumes of 100% ethanol, and was resuspended in 60 mL H20.
WGA and promoter array analyses
Immunoprecipitated DNA and input DNA from MeDIP immuno-
precipitations and MBD-Capture reactions were amplified with
GenomePlex Complete WGA Kit (Sigma catalog no. WGA2), ac-
cording to the manufacturer’s instructions. Fifty nanograms of
DNA was used in each amplification reaction. The reactions were
cleaned up using cDNA cleanup columns (Affymetrix no. 900371),
and 7.5 mg of amplified DNA was fragmented and labeled accord-
ing to Affymetrix Chromatin Immunoprecipitation Assay Protocol
P/N 702238 Rev. 3. Affymetrix GeneChip Human Promoter 1.0R
arrays (P/N. 900777) were hybridized using the GeneChip Hybrid-
ization wash and stain kit (P/N 900720).
Amplification bias experiments
WGA reactions were performed in the presence of reagents known
to enhance the amplification of GC-rich DNA (Zhang et al. 2009).
Betaine (Sigma B0300-IVL; final 2.2 M), ethylene glycol (Sigma
E-9129; lot 23H00252; final 1.075 M), 1,2 propanediol (Sigma
398039; final 0.816M), andDMSO (Stratagene catalog no. 600260-
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the amplification, the DNAwas purified, labeled, fragmented, and
hybridized to the Affymetrix GeneChip Human Promoter 1.0R
arrays as described above.
Local CpG density
We use the definition of local CpG density given by Pelizzola et al.
(2008), with a window of 600 bp (Pelizzola et al. 2008) since we
hybridize genomic DNA fragments with an average length of 600
bases, and individual probes are measuring signal from adjacent
genomic regions and are thus affected by the number of CpG sites
in this region. Briefly, the local CpG density is a weighted count of
CpG sites in the genome upstream and downstream 600 bases
from a given point of interest (e.g., microarray probe location).
Weight decreases linearly from1 at the center of the point of interest
to 0 at 600 bases up- or downstream. The score is a reflection of the
number of CpG sites in close proximity to the point of interest.
Cumulative signal attenuation
The cumulative bias score captures the degree of attenuation at
high local CpG density for a set of probes with given probe GC
content. Using the statistics (median, 25th percentile, and 75th
percentile) from bins 3–17 for each combination of probe GC
content and sample, a median and variance for the combination
were calculated. The cumulative bias is the sum of absolute de-
viations from the calculated median and variance among the 50
bins for the combination. A pictorial description is given in Sup-
plemental Figure 7.
Untargeted promoter-level analysis of promoter array data
A probe-level score for the difference of interest was calculated
(LNCaP signal PrEC signal) and smoothed using a trimmedmean
(600-bp window) and searched for a significant and persistent
difference. To calculate a false discovery rate, the order of the
probes is randomized and the same procedure is followed. The
method is implemented in the regionStats function of the Repi-
tools package (Statham et al. 2010).
Targeted promoter-level analysis of promoter
array and sequencing data
For tiling array data, a probe-level score for the difference of in-
terest was calculated (LNCaP signal  PrEC signal) using all the
probes within 750 bases of every TSS. A one-sample t-statistic was
then calculated to determinewhether the average probe-level score
for each TSS is significantly different from zero, as implemented in
the blockStats function of the Repitools package (Statham et al.
2010). P-values are calculated from t-statistics. For sequencingdata,
the number of reads that mapped to within 750 bases of every TSS
was counted. Then, an exact test for the difference in counts be-
tween LNCaP and PrEC was calculated using the Bioconductor
edgeR package (Robinson et al. 2010).
Data normalization
The normalization for Affymetrix Human Promoter 1.0R arrays
follows the adjustment proposed from themodel-based analysis of
tiling arrays (MAT) ( Johnson et al. 2006), which compensates for
the global effects of base composition and probe copy number.
By the nature of high-throughput sequencing experiments,
each sample is sequenced to a different depth. The compensation
for total read depth occurs at the following stages: (1) in the analysis
ofMBDCap-enriched SssI-treatedDNA, signal levels are presented as
read counts per million uniquely mapped, as shown in Figure 1C
(promoters) and Supplemental Figure 2 (genome); and (2) the
differential analysis of read counts at promoters, for comparing
LNCaP-MBDCap versus PrEC-MBDCap, explicitly compensates for
read depth (i.e., library size) in the edgeR software (Robinson et al.
2010).
Back-transformed Z-scores
To put observed differences between LNCaP and PrEC cells on
a common scale, for both the tiling array and sequencing plat-
forms, P-values were back-transformed into signed Z-scores. For
each P-value, the Z-score is the value, z, of the standard normal
distribution such that Pr(Z > z) = p/2, where p is the P-value. Re-
gions with higher signal (or higher relative count) in LNCaP cells
will have positive Z-scores, otherwise they will be negative.
Mapping Genome Analyzer sequencing reads
Wemapped 36 base pair reads to the hg18 reference genome using
Bowtie (Langmead et al. 2009), with up to threemismatches. Reads
that mapped more than once (i.e., identical start sites) to a single
genomic location were excluded.
Concordance of DMRs between promoter arrays
and sequencing
Promoters were deemed to be concordant and hypermethylated if
both platforms give a Z-score greater than 3 and to be concordant
and hypomethylated if both Z-scores are less than 3. Hyper-
methylated discordant promoters were defined as one platform
having a Z-score greater than 3 and the other platform with a
Z-score less than 1.5. Similarly, cutoffs of3 and1.5 were used to
define discordant hypomethylated promoters. Note that promoters
deemed as differentiallymethylated by one platform andnot by the
other (i.e., between 1 and 3 or between3 and1) are considered
indeterminate.
Down-sampling analysis
The counts were down-sampled for each gene promoter to accu-
mulate total read counts between 20% and 100% of the original
data set (10 data sets are sampled for each level of down-sampling).
For each down-sampled data set, the number of DMRs (using an
absolute Z-score cutoff of 3) was calculated. Using the median
number of DMRs for each level of subsampling, a nonlinear curve
of the form axc/(b + xc) was fitted (using the R nls function) in order
to estimate the total number of DMRs (i.e., parameter a). The 95%
confidence interval for the total number of DMRs is (5555, 6323).
The data sets sampled at 100% reveal 3777 DMRs.
Smoothed copy number estimates
The change in copy number has been smoothed using a truncated
Gaussian kernel smoother using a bandwidth of 50/200 kb (pro-
moter/SNP array), using the implementation in the aroma.core
R package (Bengtsson et al. 2008).
Mapability
Using Bowtie, all possible 36-bp reads from the entire human ge-
nome were mapped back to the genome. At every base, a read can
either be unambiguously mapped starting at a given position or
not. Mapability is the proportion of such reads that can bemapped
for a given genomic region.
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Erratum
Genome Research 20: 1719–1729 (2010)
Evaluation of affinity-based genome-wide DNA methylation data: Effects of CpG density,
amplification bias, and copy number variation
Mark D. Robinson, Clare Stirzaker, Aaron L. Statham, Marcel W. Coolen, Jenny Z. Song, Shalima S. Nair,
Dario Strbenac, Terence P. Speed, and Susan J. Clark
Panels A and B in Figure 7 were incorrectly reversed in the text and the figure legend. The corrected text and
legend are as follows:
The first full sentence in the top left column of page 1725 should read as follows:
Figure 7B illustrates changes in MBDCap-seq read counts along chromosome 13. As expected, they are
correlated with changes in copy number (Fig. 7A) for the same regions.
The corrected figure legend should read as follows:
Figure 7. Effects of copy number changes on differential methylation detection. (A) Smoothed Affymetrix
SNP 6.0 array data showing corresponding changes in copy number for human chromosome 13. (B)
Differential methylation Z-score between LNCaP and PrEC cells, using MBD-SF-seq. (C) Genome-wide
distributions of Z-scores, stratified by the change-in-copy-number status of the corresponding regions.
The authors apologize for any confusion this may have caused.
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